SITC 2023

Seagen Development Pipeline

Brentuximab Vedotin | NSCLC or Melanoma | Abstract #699

Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy

Tisotumab Vedotin | Head & Neck | Abstract #681

innovaTV 207 Parts E and F: A phase 2 study of tisotumab vedotin in patients with squamous cell carcinoma of the head and neck (trial in progress)

SGN-35T | Research | Abstract #1155

Activated regulatory T cells in solid tumors express CD30, which are selectively targeted by the novel anti-CD30 antibody-drug conjugate SGN-35T